Showing results (1041-1050 of 2,005) with videos related to
Sort By:
Pageof 201
Journal of Clinical Lipidology|May 24, 2011
Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratiosDeepthi Vodnala, Robert L Bard, Sangeetha M Krishnan, et al.Journal of Clinical Lipidology|May 24, 2011
Age is positively associated with high-density lipoprotein cholesterol among African Americans in cross-sectional analysis: the Jackson Heart StudyJane L Harman, Michael E Griswold, Neal O Jeffries, et al.Journal of Clinical Lipidology|May 24, 2011
A Mediterranean-style low-glycemic-load diet improves variables of metabolic syndrome in women, and addition of a phytochemical-rich medical food enhances benefits on lipoprotein metabolismJennifer L Jones, Maria Luz Fernandez, Mark S McIntosh, et al.Journal of Clinical Lipidology|November 24, 2011
Antisense therapy and emerging applications for the management of dyslipidemiaPeter P TothJournal of Clinical Lipidology|November 24, 2011
3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversyMaria Tzefos, Jacqueline L OlinJournal of Clinical Lipidology|October 11, 2011
Remnant-like particle cholesterol and serum amyloid A-low-density lipoprotein levels in obese subjects with metabolic syndromeKazuhiko Kotani, Noriko Asahara-Satoh, Yasuhisa Kato, et al.Journal of Clinical Lipidology|February 5, 2022
Plasma fatty acid profiles: Relationships with sex, age, and state-reported heart disease mortality rates in the United StatesMargaret R Diffenderfer, Nandani Rajapakse, Ericka Pham, et al.Journal of Clinical Lipidology|June 1, 2019
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid AssociationDon P Wilson, Terry A Jacobson, Peter H Jones, et al.Journal of Clinical Lipidology|June 17, 2019
Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trialNarendra D Lalwani, Jeffrey C Hanselman, Diane E MacDougall, et al.Journal of Clinical Lipidology|July 9, 2019
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid AssociationJennifer G Robinson, Manju Bengularu Jayanna, Alan S Brown, et al.Pageof 201